The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer

    February 2008 in “ ˜The œJournal of urology/˜The œjournal of urology ”
    Donald J. Tindall, Roger S. Rittmaster
    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Image
    Studysummary This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The review article discussed the role of inhibiting 5α-reductase isoenzymes in preventing and treating prostate cancer, emphasizing that androgens like dihydrotestosterone (DHT) are crucial for prostate growth and disease. Increased expression of 5α-reductase isoenzymes, particularly type 1, was linked to prostate cancer progression. Finasteride and dutasteride, inhibitors of these enzymes, were examined, with finasteride shown to reduce the 7-year risk of prostate cancer, while ongoing studies were evaluating dutasteride's effectiveness. The article concluded that inhibiting 5α-reductase could be a valid strategy for reducing prostate cancer risk and improving treatment outcomes.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results